Skip to main content
. Author manuscript; available in PMC: 2013 Nov 5.
Published in final edited form as: Eur J Immunol. 2012 Sep 20;42(11):10.1002/eji.201242596. doi: 10.1002/eji.201242596

Figure 1. Cross-reactive clonotypes responding to M158-66 and substituted peptides.

Figure 1

PBMC were cultured in triplicate with each peptide. TCR BV cDNA amplicons were fractionated by CDR3 length and a focused CDR3 length(s) in at least two out of three cultures used as an indicator of a specific response. Pooled data from the triplicate cultures for each peptide for all three donors are shown. Cross-reactive clonotypes that responded to the study peptides and do not use BV19 are identified in the left-most column. BV usage of the clonotypes is indicated in the next column, and each BV family is a separate color (green for BV12, pink for BV29, grey for BV18, pale blue for BV2, light brown for BV5s5, sky blue for BV15, and purple for BV24). Donors (third column from left) are indicated by different patterns and the same color/pattern is used to indicate response to the different peptides. The summary for each peptide is shown at the bottom. The column identified as XR shows the extent of cross-reactivity, which is calculated as the number of peptide-specific repertoires in which the clonotype was identified minus one. The XR range is indicated at the bottom. The number of clonotypes and peptides recognized for each BV family is in the two right-most columns, and is summarized at the bottom.